PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons	are required t	o respond to a co	llection of information unless it contains	a valid O	MB control number.	
Substitute for form 1449A/PTO			Complete if Known			
			Application Number	National Phase of PCT/		
INFORMATION DISCLOSURE				IL20	005/000196	
STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	Here	Herewith	
			First Named Inventor	Lola	Lola WEISS et al	
			Art Unit	Not	Not Yet Assigned	
		Examiner Name	Not	Not Yet Assigned		
Sheet 1	of	2	Attorney Docket Number	3236	51 ,	
	U.S.	PATENT	DOCUMENTS			
Examiner Cite Document Number Initials* No. 1	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Number-Kind Code ^{2 (if known)}						

11,

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ . Number ⁴ . Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Docume	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	PCT WO 99/53917	10-28-1999	Hampson et al.				
	2	PCT WO 03/063847	07-7-2003	Whittle et al.				
Examine Signatur		/Jennifer Kim/		Date Considere	d 06/08/2010			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Trisisation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10/589623MSR Rosto 10 Feb. 0 1 6 AUG 2006

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number National Phase of INFORMATION DISCLOSURE PCT/ IL2005/000196 STATEMENT BY APPLICANT Herewith Filing Date Lola WEISS et al (use as many sheets as necessary) First Named Inventor Group Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Sheet 2 32361 Attorney Docket Number 32361 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T² Initials No. publisher, city and/or country where published. 3 ??? "Cannabis-Based Medicines - GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis - GW Pharmaceuticals, THC: CBD", Drugs R&D, 4(5): 306-309, 2003. P.307, 4th Full §. Weiss et al. "Cytokine Production in Linomide-Treated Nod Mice and the Potential 4 Role of A Th1/Th2 Shift on Autoimmune and Anti-Inflammatory Processes", Cytokine, 19(2): 85-93, 2002. Fig. 1, 4, P.87-91, § entitled "Discussion". Srivastava et al. "Δ9 Tetrahydrocannabinol and Cannabidiol Alter Cytokine 5 Production by Human Immune Cells", Immunopharmacology, 40(3): 179-185, 1998. P.183-184, § entitled "Discussion".

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Signature

/Jennifer Kim/

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Considered

06/08/2010